New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2014
09:09 EDTCURNeuralstem raises $19.65M in a registered direct offering
Neuralstem announced that it has entered into agreements with leading institutional investors for a registered direct placement of 6,752,744 shares of common stock at a price of $2.91 per share, resulting in aggregate gross proceeds of approximately $19.65 million. T.R. Winston & Company, LLC acted as the exclusive placement agent for the offering.
News For CUR From The Last 14 Days
Check below for free stories on CUR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
09:19 EDTCURNeuralstem ALS investigator presents long-term follow up Phase I data
Neuralstem announced that Jonathan D. Glass, MD, site investigator at Emory University, presented long-term follow up data on the Phase I trial testing NSI-566 human neural stem cells in the treatment of amyotrophic lateral sclerosis, or ALS. The presentation, which occurred at the Annual Symposium on ALS of the Foundation Andre-Delambre, in Montreal, Canada, on Friday, and was not open to the public, covered data up to approximately 1200 days post the stem cell treatment. Dr. Glass reported that patients in the last safety cohort, who received treatments in both the lumbar and the cervical region with the highest number of cells per injection, all showed significant slowing of the progression of the disease. One patient showed functional improvement from pre-treatment baseline, which is maintained to present day. The other two patients are maintaining the same level of functionality as they had at the baseline for over three years since the stem cell treatment. "The long-term follow up data is very encouraging," said Karl Johe, PhD, Neuralstem's Chairman and Chief Scientific Officer. "In Phase I, patients 10, 11, and 12 each received 10 lumbar and five cervical injections, of 100,000 cells each, which was far below the safe maximal dose. Even so, the data shows a significant slowing of the disease progression for over three years. If replicated on a larger scale, this could represent meaningful improvement in quality of life, and lifespan, compared to untreated patients. In our Phase II dose escalation trial, we successfully reached the maximal dose planned, which consisted of 20 lumbar and 20 cervical injections of 400,000 cells each, more than ten times the number of stem cells delivered in the highest dose cohort of the Phase I trial."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use